Kudo M - Search Results

1

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.

Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, Kudo M, Finn RS. Llovet JM, et al. Among authors: kudo m. Nat Rev Clin Oncol. 2024 Apr;21(4):294-311. doi: 10.1038/s41571-024-00868-0. Epub 2024 Feb 29. Nat Rev Clin Oncol. 2024. PMID: 38424197 Review.

2

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:1-12. doi: 10.1159/000181865. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092266 Review.

3

Impact of interferon therapy after curative treatment of hepatocellular carcinoma.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:30-41. doi: 10.1159/000173422. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092270

4

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.

Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, Hatanaka K, Kitai S, Ishikawa E, Inoue T, Hagiwara S, Minami Y, Chung H. Ueshima K, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:106-13. doi: 10.1159/000173431. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092279

5

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.

Kudo M. Kudo M. Int J Clin Oncol. 2010 Jun;15(3):242-55. doi: 10.1007/s10147-010-0089-y. Epub 2010 May 28. Int J Clin Oncol. 2010. PMID: 20509038 Review.

6

Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010.

Kudo M. Kudo M. Oncology. 2010 Jul;78 Suppl 1:113-24. doi: 10.1159/000315239. Epub 2010 Jul 8. Oncology. 2010. PMID: 20616593 Review.

7

Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma.

Llovet JM, Paradis V, Kudo M, Zucman-Rossi J. Llovet JM, et al. Among authors: kudo m. Liver Transpl. 2011 Oct;17 Suppl 2(Suppl 2):S67-71. doi: 10.1002/lt.22340. Liver Transpl. 2011. PMID: 21594967 Free PMC article. Review. No abstract available.

8

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.

Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Clavien PA, et al. Lancet Oncol. 2012 Jan;13(1):e11-22. doi: 10.1016/S1470-2045(11)70175-9. Epub 2011 Oct 31. Lancet Oncol. 2012. PMID: 22047762 Free PMC article.

9

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. Llovet JM, et al. Among authors: kudo m. J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980090 Clinical Trial.

10

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.

Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, Wu C, Tanwandee T, Shao G, Walters IB, Dela Cruz C, Poulart V, Wang JH. Kudo M, et al. Hepatology. 2014 Nov;60(5):1697-707. doi: 10.1002/hep.27290. Epub 2014 Sep 29. Hepatology. 2014. PMID: 24996197 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,477 results

Search Page